Literature DB >> 26617070

Tryptophan availability for kynurenine pathway metabolism across the life span: Control mechanisms and focus on aging, exercise, diet and nutritional supplements.

Abdulla A-B Badawy1.   

Abstract

Tryptophan (Trp) availability for the kynurenine pathway (KP) across the life span is discussed. Free (non-albumin-bound) plasma Trp is the major determinant of the flux of Trp down the KP. Flux is the major determinant of kynurenine metabolite formation and is more effective than induction of hepatic Trp 2,3-dioxygenase (TDO) or extrahepatic indoleamine 2,3-dioxygenase (IDO). Flux is better expressed using the sum of plasma kynurenine and its metabolites, rather than kynurenine only. Under normal conditions, TDO controls Trp flux in liver and availability in plasma and can supply kynurenine for the extrahepatic pathway. Under certain pathological conditions associated with immune activation, IDO assumes the major role in control of Trp availability. Plasma Trp availability is increased during pregnancy, at birth, and by exercise, high protein and fat intake. Aging does not seem to exert a major effect on plasma Trp. Assessment of plasma Trp availability in health and disease requires measurement of concentrations of both free and total [Trp] in the first instance, followed, if necessary, by those of albumin and the physiological displacers of albumin-bound Trp, non-esterified fatty acids. Additional measures should include cortisol, cytokines, kynurenine and its metabolites. This article is part of the Special Issue entitled 'The Kynurenine Pathway in Health and Disease'. Copyright Â
© 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Albumin; Glucose; Indoleamine 2,3-dioxygenase; Non-esterified fatty acids; Tryptophan 2,3-dioxygenase

Mesh:

Substances:

Year:  2015        PMID: 26617070     DOI: 10.1016/j.neuropharm.2015.11.015

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  54 in total

Review 1.  Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?

Authors:  Lu Jiang; Bernd Schnabl
Journal:  Physiology (Bethesda)       Date:  2020-07-01

2.  Assessment of Prenatal Kynurenine Metabolism Using Tissue Slices: Focus on the Neosynthesis of Kynurenic Acid in Mice.

Authors:  Francesca M Notarangelo; Sarah Beggiato; Robert Schwarcz
Journal:  Dev Neurosci       Date:  2019-05-22       Impact factor: 2.984

Review 3.  The kynurenine pathway and the brain: Challenges, controversies and promises.

Authors:  Robert Schwarcz; Trevor W Stone
Journal:  Neuropharmacology       Date:  2016-08-07       Impact factor: 5.250

4.  Hypertryptophanemia due to tryptophan 2,3-dioxygenase deficiency.

Authors:  Patrick Ferreira; Inchul Shin; Iveta Sosova; Kednerlin Dornevil; Shailly Jain; Deborah Dewey; Fange Liu; Aimin Liu
Journal:  Mol Genet Metab       Date:  2017-03-01       Impact factor: 4.797

5.  Assessment of Tryptophan Uptake and Kinetics Using 1-(2-18F-Fluoroethyl)-l-Tryptophan and α-11C-Methyl-l-Tryptophan PET Imaging in Mice Implanted with Patient-Derived Brain Tumor Xenografts.

Authors:  Sharon K Michelhaugh; Otto Muzik; Anthony R Guastella; Neil V Klinger; Lisa A Polin; Hancheng Cai; Yangchun Xin; Thomas J Mangner; Shaohui Zhang; Csaba Juhász; Sandeep Mittal
Journal:  J Nucl Med       Date:  2016-10-20       Impact factor: 10.057

6.  Kynurenine, a Tryptophan Metabolite That Accumulates With Age, Induces Bone Loss.

Authors:  Mona El Refaey; Meghan E McGee-Lawrence; Sadanand Fulzele; Eileen J Kennedy; Wendy B Bollag; Mohammed Elsalanty; Qing Zhong; Ke-Hong Ding; Nathaniel G Bendzunas; Xing-Ming Shi; Jianrui Xu; William D Hill; Maribeth H Johnson; Monte Hunter; Jessica L Pierce; Kanglun Yu; Mark W Hamrick; Carlos M Isales
Journal:  J Bone Miner Res       Date:  2017-08-14       Impact factor: 6.741

7.  Tryptophan Metabolism and White Matter Integrity in Schizophrenia.

Authors:  Joshua Chiappelli; Teodor T Postolache; Peter Kochunov; Laura M Rowland; S Andrea Wijtenburg; Dinesh K Shukla; Malle Tagamets; Xiaoming Du; Anya Savransky; Christopher A Lowry; Adem Can; Dietmar Fuchs; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2016-05-04       Impact factor: 7.853

8.  Glia- and tissue-specific changes in the Kynurenine Pathway after treatment of mice with lipopolysaccharide and dexamethasone.

Authors:  Carlos R Dostal; Nicolaus S Gamsby; Marcus A Lawson; Robert H McCusker
Journal:  Brain Behav Immun       Date:  2017-12-11       Impact factor: 7.217

Review 9.  Kynurenines and Glutamate: Multiple Links and Therapeutic Implications.

Authors:  R Schwarcz
Journal:  Adv Pharmacol       Date:  2016-03-11

10.  Kynurenine suppresses osteoblastic cell energetics in vitro and osteoblast numbers in vivo.

Authors:  Jessica L Pierce; Rachel L Roberts; Kanglun Yu; Riley K Kendall; Helen Kaiser; Colleen Davis; Maribeth H Johnson; William D Hill; Carlos M Isales; Wendy B Bollag; Mark W Hamrick; Meghan E McGee-Lawrence
Journal:  Exp Gerontol       Date:  2019-12-17       Impact factor: 4.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.